Brief: Cyclo Therapeutics Announces Positive Data From Study Of Trappsol Cyclo
30/07/2021 13:25
July 30 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS ANNOUNCES NEW POSITIVE SAFETY AND
EFFICACY
DATA FROM ONGOING PHASE 1 OPEN-LABEL EXTENSION STUDY OF TRAPPSOL
CYCLO FOR TREATMENT OF NIEMANN-PICK DISEASE TYPE C1
* CYCLO THERAPEUTICS - FAVORABLE SAFETY PROFILE OF TRAPPSOL
CYCLO
ADMINISTERED INTRAVENOUSLY FOR MORE THAN 2 YEARS
* CYCLO THERAPEUTICS - PIVOTAL PHASE 3 STUDY
("TRANSPORTNPC")
CURRENTLY OPEN FOR PATIENT ENROLLMENT
Source text for Eikon: ID:nBw9sXlSfa
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug